BTemplates.com

Powered by Blogger.

Pageviews past week

Quantum mechanics

Auto News

artificial intelligence

About Me

Recommend us on Google!

Information Technology

Popular Posts

Showing posts with label Pharmaceutical drug. Show all posts
Showing posts with label Pharmaceutical drug. Show all posts

Tuesday, March 30, 2010

Contact Lenses Loaded With Vitamin E May Treat Glaucoma


The popular dietary supplement vitamin E, loaded into special medicated contact lenses, can keep glaucoma medicine near the eye -- where it can treat that common disease -- almost 100 times longer than possible with current commercial lenses, scientists report.

Me
Contact lenses containing vitamin E like the one above can treat glaucoma, the second leading cause of blindness, and other eye conditions, scientists are reporting. (Credit: Anuj Chauhan, Ph.D.)
In a presentation at the 239th National Meeting of the American Chemical Society (ACS) in San Francisco, they described use of vitamin E to develop contact lenses that may deliver more medication for glaucoma and perhaps other diseases to the eye.

Anuj Chauhan, Ph.D., who headed the research team, explained that glaucoma is second only to cataracts as the leading cause of vision loss and blindness in the world. It affects almost 67 million people. Eye drops that relieve the abnormal build-up of pressure inside the eye that occurs in glaucoma, are a mainstay treatment.

"The problem is within about two to five minutes of putting drops in the eye, tears carry the drug away and it doesn't reach the targeted tissue," said Chauhan, who is with the University of Florida in Gainesville. "Much of the medicine gets absorbed into the bloodstream, which carries it throughout the body where it could cause side effects. Only about one to five percent of drugs in eye drops actually reach the cornea of the eye."

Chauhan and colleagues have developed a new extended-release delivery approach incorporating vitamin E into contact lenses. The invisible clusters, or aggregates, of vitamin E molecules form what Chauhan describes as "transport barriers." that slow down the elusion of the glaucoma medication from the lens into the eye. The drug released from the lens into the eye stays in the tears far longer than the 2-5 minutes with eye drops, leading to more effective therapy.

"These vitamin structures are like 'nano-bricks'," Chauhan said. "The drug molecules can't go through the vitamin E. They must go around it. Because the nanobricks are so much bigger than the drug molecules -- we believe about a few hundred times bigger -- the molecules get diverted and must travel a longer path. This increases the duration of the drug release from the lenses."

In research with laboratory animals, the lenses containing vitamin E nanobricks administered drugs up to 100 times longer than most commercial lenses. The lenses could be designed for continuous wear for up to a month, Chauhan said. In addition to treating glaucoma, the contacts could help other eye conditions, such as cataract and dry eye. Cataract is a clouding of the lens of the eye, and dry eye involves decreased production of tears. It affects about 2 in 10 people and can lead to more severe eye problems.

"Vitamin E is a proven nutraceutical that in small amounts is good for the eye because of its ant-oxidant properties. Also Vitamin E presence in the contact lenses blocks UV radiation, leading to increased protection against the UV light. Our research has shown that the vitamin can be loaded into the lenses without any reduction in transparency. We believe it could be helpful in disease treatment and in prevention as well," he said.

Chauhan said that clinical trials of the new lenses could begin within a year to 2 years.

Here is an excerpt from Chauhan's ACS presentation:

"We have developed a novel approach of extending the duration of drug release from contact lenses by including nanosized aggregates of Vitamin E in the lenses. The Vitamin E nano-aggregates force the drug molecules to travel in a tortuous path leading to increased drug release durations. Another benefit of Vitamin E incorporation is that Vitamin E is known to be an anti-oxidant, whose slow release from lenses could also help in prevention of ophthalmic diseases like cataract and glaucoma. Furthermore, Vitamin E blocks UV radiation, leading to reduced ocular damage from the UV light. Our research has shown that Vitamin E can be loaded into the lenses without any reduction in transparency. The drug release durations from Vitamin E loaded lenses are about 100 times longer than from commercial lenses for several ophthalmic drugs including glaucoma drug timolol, anti-inflammatory drug dexamethasone, and anti-viral drug flucanozole. Thus, Vitamin E loaded lenses could be highly effective in synergistic prevention and treatment of ophthalmic diseases through extended delivery of the desired drugs and the nutraceutical Vitamin E. Animal studies in beagle dogs are ongoing to explore glaucoma treatment through Vitamin E laden contact lenses."
Reblog this post [with Zemanta]

Sunday, November 8, 2009

Computational Method Points To New Uses, Unexpected Side Effects Of Already Existing Drugs


Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs.

Bryan Roth, M.D., Ph.D. (Credit: Image courtesy of University of North Carolina School of Medicine)



The researchers developed a computational method that compares how similar the structures of all known drugs are to the naturally occurring binding partners -- known as ligands -- of disease targets within the cell. In a study published this week in Nature, the scientists showed that the method predicts potential new uses as well as unexpected side effects of approved drugs.

Wednesday, June 24, 2009

Model Livers to Replace Lab Rats


German researchers have developed an external model of the liver, which could provide a safer alternative to animal experiments

If you have fever, headaches or a cold, it’s only a short way to the nearest chemist. The drugs, on the other hand, can take up to eight to ten years to develop.

Animal testing has been an essential step in testing drugs, but it continues to raise ethical issues. Furhermore,
humans and animals have different metabolisms, and around 30 per cent of side effects come to light in trials following animal experiments.

Researchers at the the Fraunhofer Institute have developed a model of the liver, which is viable outside the body and is suitable for testing drugs.

“Our artificial organ systems offer an alternative to animal experiments,” said Heike Mertsching, Professor at the Interfacial Engineering and Biotechnology Institute at Fraunhofer.

The test system, which Professor Mertsching has developed jointly with Dr Johanna Schanz, should in future give pharmaceutical companies more security and shorten the path to developing and releasing new drugs.

“Our liver model is a functioning system of blood vessels,” said Dr. Schanz. “We don’t build artificial blood vessels, but use existing ones – from a piece of pig’s intestine.”

All of the pig cells are removed, but the blood vessels are preserved. Human cells are then seeded onto this structure – hepatocytes, which are responsible for breaking down drugs, and endothelial cells, which act as a barrier between blood and tissue cells.

In order to simulate circulation, the researchers put the model into a computer-controlled bioreactor with a flexible tube pump. This enables the nutrient solution to be fed in and carried away in the same way as in veins and arteries in humans.

“The cells were active for up to three weeks,” said Dr. Schanz. “This time was sufficient to analyse and evaluate the functions. A longer period of activity is possible, however.”

The researchers established that the cells work in a similar way to those in the body. They detoxify, break down drugs and build up proteins. These are important pre-conditions for drug tests or transplants, as the effect of a substance can change when transformed or broken down. Many drugs are only metabolised into their therapeutic active form in the liver, while others can develop poisonous substances.

At the moment, the test system is being examined. The researchers say it could provide an alternative to animal testing within two years.


If you like this post, buy me a beer at $3!
Reblog this post [with Zemanta]